After a string of high-profile…
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes [...]
With sales of Immunocore’s…
With sales of Immunocore’s melanoma medicine steadily ticking up, an [...]
Messenger RNA specialist Moderna’s…
Messenger RNA specialist Moderna’s R&D spend sunk by nearly a [...]
Ultragenyx’s employees were…
Ultragenyx’s employees were already braced for changes as the biopharma [...]
Sanofi is replacing CEO Paul…
Sanofi is replacing CEO Paul Hudson with Merck KGaA leader [...]
After scrapping one portion of the…
After scrapping one portion of the trial, Lundbeck’s intravenous monoclonal [...]
Just months after laying off a…
Just months after laying off a quarter of its workforce [...]
BridgeBio is hoping that…
BridgeBio is hoping that infigratinib will get another shot at [...]
For all of the groundbreaking…
For all of the groundbreaking advancements in cancer treatment over [...]
Madrigal Pharmaceuticals is…
Madrigal Pharmaceuticals is continuing to splash the cash this year [...]